Harnessing genotype and phenotype data for population-scale variant classification using large language models and bayesian inference

Variants of Uncertain Significance (VUS) in genetic testing for hereditary diseases burden patients and clinicians, yet clinical data that could reduce VUS are underutilized due to a lack of scalable strategies. We assessed whether a machine learning approach using genotype and phenotype data could improve variant classification and reduce VUS. In this cohort study of a multi-step machine learning approach, patient data from test requisition forms were used to distinguish patients with molecular diagnoses from controls ("patient score"). A generative Bayesian model then used patient scores and variant classifications to infer variant pathogenicity ("variant score"). The study included 3.5 million patients referred for clinical genetic testing across various conditions. Primary outcomes were model- and gene-level discrimination, classification performance, probabilistic calibration, and concordance with orthogonal pathogenicity measures. Integration into a semi-quantitative classification framework was based on posterior pathogenicity probabilities matching PPV ≥ 0.99/NPV ≥ 0.95 thresholds, followed by expert review. We generated 1,334 clinical variant models (CVMs); 595 showed high performance in both machine learning steps (AUROCpatient ≥ 0.8 and AUROCvariant ≥ 0.8) on held-out data. High-confidence predictions from these CVMs provided evidence for 5,362 VUS observed in 200,174 patients, representing 23.4% of all VUS observations in these genes. In 17 frequently tested genes, CVMs reclassified over 1,000 unique VUS, reducing VUS report rates by 9-49% per condition. In conclusion, a scalable machine learning approach using underutilized clinical data improved variant classification and reduced VUS.

Authors

Institutions

Publication Details

Journal
Human Genetics
Published
2025-04-23
DOI
https://doi.org/10.1007/s00439-025-02743-z
Citations
2
Primary Topic
Genomics and Rare Diseases
Type
article
Field-Weighted Citation Impact
3.63
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Harnessing genotype and phenotype data for population-scale variant classification using large language models and bayesian inference

Laure Frésard, Alexandre Colavin, Samskruthi Reddy Padigepati, Toby Manders et al.
2 citations
Human Genetics
Genomics and Rare Diseases
3.63
article

Harnessing genotype and phenotype data for population-scale variant classification using large language models and bayesian inference

Laure Frésard, Alexandre Colavin, Samskruthi Reddy Padigepati, Toby Manders, Jason Reuter, Flavia M. Facio, Robert L. Nussbaum, David Stafford, Keith Nykamp, Carlos L. Araya, Hillery C. Metz, Yuya Kobayashi, Alexander Wahl, Christopher Tan
article en
2 citations

Abstract

Variants of Uncertain Significance (VUS) in genetic testing for hereditary diseases burden patients and clinicians, yet clinical data that could reduce VUS are underutilized due to a lack of scalable strategies. We assessed whether a machine learning approach using genotype and phenotype data could improve variant classification and reduce VUS. In this cohort study of a multi-step machine learning approach, patient data from test requisition forms were used to distinguish patients with molecular diagnoses from controls ("patient score"). A generative Bayesian model then used patient scores and variant classifications to infer variant pathogenicity ("variant score"). The study included 3.5 million patients referred for clinical genetic testing across various conditions. Primary outcomes were model- and gene-level discrimination, classification performance, probabilistic calibration, and concordance with orthogonal pathogenicity measures. Integration into a semi-quantitative classification framework was based on posterior pathogenicity probabilities matching PPV ≥ 0.99/NPV ≥ 0.95 thresholds, followed by expert review. We generated 1,334 clinical variant models (CVMs); 595 showed high performance in both machine learning steps (AUROCpatient ≥ 0.8 and AUROCvariant ≥ 0.8) on held-out data. High-confidence predictions from these CVMs provided evidence for 5,362 VUS observed in 200,174 patients, representing 23.4% of all VUS observations in these genes. In 17 frequently tested genes, CVMs reclassified over 1,000 unique VUS, reducing VUS report rates by 9-49% per condition. In conclusion, a scalable machine learning approach using underutilized clinical data improved variant classification and reduced VUS.

Human GeneticsVol. 144(6)
GenVec (US), LabCorp (United States) (US), Threshold Pharmaceuticals (United States) (US), University of California San Francisco Medical Center (US), Invitae (United States) (US)
Openalex Percentile: Top 8%
Genomics and Rare Diseases
3.63
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.